Introduction. Optimal anticoagulants for patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI) are unclear. This retrospective observational study is aimed at evaluating efficacy and safety of bivalirudin versus unfractionated heparin (UFH) monotherapy in patients with DM undergoing PCI. Methods. A total of 3890 diabetic patients receiving PCI in the General Hospital of Northern Theater Command were divided into the bivalirudin group \( (n = 869) \) and the UFH group \( (n = 3021) \) according to different anticoagulant therapy regimens. Indication for PCI was in accordance with current guidelines including national cardiovascular data registry. The primary endpoint was 30-day net adverse clinical events (NACEs). The secondary endpoints included 30-day major adverse cardiac and cerebral events (MACCEs), bleeding events defined according to the Bleeding Academic Research Consortium (BARC) definition, and stent thrombosis (ST). Patients were matched by propensity score at a ratio of 1 : 1. Results. After propensity score matching, the bivalirudin group was associated with a lower incidence of NACEs (3.0% vs. 6.0%, \( P = 0.003 \)) than the UFH group. The incidence of MACCE (1.7% vs. 3.3%, \( P = 0.033 \)) was significantly lower in the bivalirudin group, mainly due to a lower mortality rate (0.6% vs. 2.0%, \( P = 0.010 \)). In addition, patients in the bivalirudin group had less bleeding (1.4% vs. 3.0%, \( P = 0.022 \)) than those in the UFH group, although BARC 2, 3, and 5 bleeding (0.1% vs. 0.6%, \( P = 0.218 \)) was numerically lower. Conclusion. In diabetic patients undergoing PCI, bivalirudin was significantly associated with reduced risks of 30-day NACE and MACCE, mainly driven by the lower rates of bleeding and mortality, compared with heparin monotherapy.

1. Introduction

Although patients with diabetes mellitus (DM) and coronary artery disease (CAD) have an increased risk for ischemic events such as myocardial infarction (MI) and stent thrombosis (ST) compared to patients without DM [1, 2], previous studies have also demonstrated a higher rate of bleeding in this population, which is known to be significantly associated with mortality [3–5]. Due to the dilemma of balancing ischemic and bleeding risks, it is a challenge to determine antithrombotic strategies during PCI procedure in patients with DM.
current guidelines because of the high risk of bleeding [13, 14]. Currently, evidence comparing bivalirudin with UFH monotherapy is limited, especially among diabetic patients undergoing PCI. Therefore, we performed an observational study evaluating the efficacy and safety of bivalirudin monotherapy versus heparin monotherapy in patients with DM undergoing PCI in a real-world cohort.

2. Materials and Methods

2.1. Study Population. This single-center, observational study recruited the consecutive patients with DM and CAD who underwent PCI from January 2016 to November 2018 in the Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China. Indication for PCI was in accordance with national cardiovascular data registry, which includes (1) elective; (2) urgent (required during same hospitalization to minimize further clinical deterioration, worsening or sudden chest pain, congestive heart failure, acute MI, anatomy, intra-aortic balloon pump, unstable angina with intravenous nitroglycerin, or angina at rest); (3) emergency (to procedure or in transit to the catheterization laboratory, ongoing ischemia despite maximal medical therapy, acute MI ≤24 hours before procedure, pulmonary edema requiring intubation, or shock with or without circulatory support); or (4) salvage (undergoing CPR enroute to PCI). The inclusion criteria were as follows: (1) age ≥18; (2) DM treated with insulin and/or oral agents; (3) at least one stent implemented; and (4) usage of bivalirudin or UFH during the procedure. The exclusion criteria were as follows: (1) administration of both bivalirudin and UFH during PCI; (2) the use of low-molecular-weight heparin; (3) cardiogenic shock; (4) aortic dissection; or (5) planned secondary PCI within 30 days. This study was approved by the Ethics Committee of General Hospital of Northern Theater Command, and an exemption for informed consent was approved simultaneously.

2.2. Medications. Bivalirudin was administered as a bolus of 0.75 mg/kg before the procedure, followed by infusion of 1.75 mg/kg/hour during the procedure and prolonged infusion at the PCI dose for at least 30 minutes after the procedure. For patients who used UFH, a bolus of 80–100 U/kg was administered. The activated clotting time (ACT) was measured using a Haemotec system 5 minutes after the bolus. An additional bivalirudin (0.3 mg/kg) or UFH (20 U/kg) bolus was given if the ACT was less than 225 seconds in the bivalirudin group or 200 seconds in the UFH group, respectively. GPIs were used only for bail-out only if there was evidence for no-reflow or a thrombotic complication. Antiplatelet therapy with aspirin and a P2Y12 inhibitor loading was regularly prescribed according to concurrent guidelines. After the procedure, all patients received clopidogrel (75 mg/day) or ticagrelor (180 mg/day) in combination with aspirin (100 mg/day) for at least 12 months. Other medications were given in the physician’s direction according to standard local practice.

2.3. Data Collection and Follow-Up. Baseline clinical characteristics, laboratory tests, medications, and procedural characteristics were obtained from the hospital information system. Data were screened upon entry, and inaccurate data were checked, corrected, or cleared up. All participants were regularly followed up via centralized telephone or e-mail by trained personnel at 1, 6, and 12 months after the procedure and patients who could not be contacted over three times were considered lost to follow-up. Thirty-day clinical outcomes were extracted from the follow-up database. All clinical events were adjudicated by three experienced cardiologists who were blinded to the treatment allocations.

2.4. Study Endpoints. The primary endpoint was net adverse clinical events (NACEs) at 30 days after the procedure, defined as a composite of death, MI, stroke, urgent target lesion revascularization (uTLR), or any bleeding. The secondary endpoints were major adverse cardiovascular and cerebral events (MACCEs) at 30 days, defined as a composite of death, MI, stroke, and uTLR. MI was defined based on the Fourth Universal Definition of Myocardial Infarction Guidelines [15]. Stroke was defined as local or systemic loss of neurologic function attributable to a central nervous system vascular cause lasting for at least 24 h, documented by a CT scan or magnetic resonance imaging (MRI) or autopsic evidence. Other secondary endpoints included ST and any bleeding. Bleeding was defined according to Bleeding Academic Research Consortium (BARC) criteria [16], and ST was defined in accordance with the Academic Research Consortium definitions [17].

2.5. Statistical Analysis. Continual variables are presented as the mean ± standard deviation (SD) and were compared using the Student t test. Categorical data are presented as counts (%) and were compared using the χ² test or Fisher’s exact test, as appropriate. To minimize the selection bias, propensity score matching (PSM) was conducted. Patients were matched at a ratio of 1:1 between the bivalirudin and UFH groups using nearest-neighbor matching. Variables matched by propensity score included age, sex, smoking status, drinking status, hypertension, history of stroke, MI, PCI and coronary artery bypass graft (CABG), peripheral arterial disease (PAD), clinical presentation, estimated glomerular filtration rate (eGFR), left ventricular ejection fraction (LVEF), level of hemoglobin (Hb), platelet count, CRUSADE score, medications at discharge, radial or femoral access, target vessels, chronic total occlusion, length, diameter and number of stents, and SYNTAX score. The incidences of NACE, MACCE, bleeding, and death were compared between the two groups using Kaplan-Meier curves and tested by log-rank tests both before and after PSM. A two-tailed p value less than 0.05 was considered to be statistically significant. Statistical analyses were performed using IBM SPSS (version 22).

3. Results and Discussion

3.1. Baseline Characteristics. Among 15,427 patients undergoing PCI from January 2016 to November 2018 in the
Department of Cardiology, General Hospital of Northern Theater Command, 3890 patients with DM were enrolled in our study (Figure 1). A total of 869 (22.3%) patients received bivalirudin and 3021 (77.7%) patients received UFH during the perioperative period. Most patients (94.0%) received PCI via a transradial approach, and 1406 (36.1%) patients presented with acute MI (Table 1). Compared with the UFH group, patients in the bivalirudin group were older, more likely to be female, and have a history of prior stroke. The proportion of ST-segment elevation myocardial infarction was higher in the bivalirudin group than in the UFH group. In addition, eGFR, level of Hb, platelet count, and the ratio of radial access were lower and CRUSADE scores were higher in patients with bivalirudin than in those with UFH. The proportion of use of GPIs in the two groups was 15.1% and 13.3%, respectively ($P = 0.038$) (Table 1). After PSM, baseline characteristics, including the proportion of GPI administration (13.6% vs. 13.3%, $P = 0.888$), were well balanced between the two groups.

At 30 days, the primary endpoint, NACE, occurred in 26 (3.0%) patients in the bivalirudin group and 151 (5.0%) patients in the UFH group (Table 2). The risk of NACE was significantly lower in the bivalirudin group than in the UFH group irrespective of whether PSM was performed (before PSM: 3.0% vs. 5.0%, $P = 0.012$; after PSM: 3.0% vs. 6.0%, $P = 0.003$, Figures 2(a) and 2(b)). The significant difference was driven by both the lower rates of BARC-defined any bleeding (before PSM: 1.4% vs. 2.6%, $P = 0.038$; after PSM: 1.4% vs. 3.0%, $P = 0.022$, Figures 3(a) and 3(b)) and the reduction of MACCE (before PSM: 1.7% vs. 2.5%, $P = 0.175$; after PSM: 1.7% vs. 3.3%, $P = 0.033$, Figures 2(c) and 2(d)).

The lower incidence of MACCEs was mainly ascribed to a significantly lower rate of death (before PSM: 0.6% vs. 1.1%, $P = 0.151$; after PSM: 0.6% vs. 2.0%, $P = 0.033$, Figures 3(c) and 3(d)) in the bivalirudin group than in the UFH group. The rates of MI, stroke, and uTLR were similar between the two groups. In terms of the safety endpoint, although without significant difference, the rate of BARC type 2, 3, and 5 bleeding in the bivalirudin group was quantitatively lower than that in the heparin group (before PSM: 0.1% vs. 0.3%, $P = 0.577$; after PSM: 0.1% vs. 0.6%, $P = 0.218$). The 30-day ST occurred in only 2 patients in each group, including 2 definite ST (0.1%) in heparin group and 2 probable ST (0.2%) in bivalirudin group. No statistically significant difference in the rate of ST was found between the two groups (before PSM: 0.2% vs. 0.1%, $P = 0.218$; after PSM: 0.2% vs. 0.1%, $P = 1.000$) (Table 2). No interaction in the rate of NACE, MACCE, or all bleeding was found between CKD or no-CKD (defined as eGFR < 60 mL/min/1.73 m²), or between transradial or transfemoral approach ($P$ for interaction > 0.05 for both, Supplemental Materials Table S1).
Table 1: Baseline characteristics.

| Variable                      | Before PSM | After PSM | P value |
|-------------------------------|------------|-----------|---------|
| Age (year)                    | 63.80 ± 9.91 | 60.99 ± 9.69 | <0.001 |
| Female                        | 309 (35.6)  | 309 (35.6)  | 0.960  |
| Smoker                        | 279 (32.1)  | 279 (32.1)  | 0.171  |
| Drinker                       | 130 (15.0)  | 130 (15.0)  | 0.641  |
| Hypertension                  | 620 (71.3)  | 620 (71.3)  | 0.093  |
| Previous MI                   | 180 (20.7)  | 180 (20.7)  | 0.766  |
| Previous PCI                  | 255 (29.3)  | 255 (29.3)  | 0.833  |
| Previous CABG                 | 14 (1.6)    | 14 (1.6)    | 0.475  |
| Peripheral arterial disease   | 19 (2.2)    | 19 (2.2)    | 0.488  |

Clinical presentation

| SCAD                         | 1 (0.1)   | 2 (0.1)    | 0.532  |
| UA                           | 511 (58.8) | 511 (58.8) | 500 (57.5) | 0.593 |
| AMI                          | 355 (40.9) | 355 (40.9) | 361 (41.5) | 0.770 |
| NSTEMI                       | 157 (18.1) | 157 (18.1) | 150 (17.3) | 0.660 |
| STEMI                        | 198 (22.8) | 198 (22.8) | 211 (24.3) | 0.462 |
| eGFR (L-min⁻¹·1.73 m⁻³)      | 100.14 ± 36.78 | 100.14 ± 36.78 | <0.001 |
| Hb (g/L)                     | 132.42 ± 17.44 | 132.42 ± 17.44 | <0.001 |
| Platelet count (10⁹/L)       | 218.03 ± 61.24 | 218.03 ± 61.24 | <0.001 |
| LVEF (%)                     | 58.75 ± 9.10  | 58.75 ± 9.10  | 58.67 ± 8.95 | 0.851 |
| CRUSADE score                | 34.00 ± 13.53 | 34.00 ± 13.53 | <0.001 |

Antiplatelet therapy before PCI

| Aspirin                      | 858 (98.7) | 858 (98.7) | 859 (98.8) | 0.826 |
| Clopidogrel                  | 789 (90.8) | 789 (90.8) | 782 (90.0) | 0.569 |
| Ticagrelor                   | 226 (26.0) | 226 (26.0) | 200 (23.0) | 0.147 |

Medications at discharge

| Aspirin                      | 842 (96.9) | 842 (96.9) | 850 (97.8) | 0.232 |
| Clopidogrel                  | 622 (71.6) | 622 (71.6) | 635 (73.1) | 0.486 |
| Ticagrelor                   | 237 (27.3) | 237 (27.3) | 220 (25.3) | 0.354 |
| Statin                       | 812 (93.4) | 812 (93.4) | 813 (93.6) | 0.922 |
| ACEI                         | 435 (50.1) | 435 (50.1) | 436 (50.2) | 0.962 |
| ARB                          | 182 (20.9) | 182 (20.9) | 172 (19.8) | 0.551 |
| β-Blocker                    | 657 (75.6) | 657 (75.6) | 646 (74.3) | 0.542 |
| CCB                          | 235 (27.0) | 235 (27.0) | 227 (26.1) | 0.664 |

| Target vessel                | 799 (91.9) | 799 (91.9) | 818 (94.1) | 0.073 |
| LM                           | 42 (4.8)   | 42 (4.8)   | 38 (4.4)   | 0.647 |
| LAD                          | 341 (39.2) | 341 (39.2) | 341 (50.0) | 1.000 |
| LCX                          | 188 (21.6) | 188 (21.6) | 166 (19.1) | 0.190 |
| RCA                          | 270 (31.1) | 270 (31.1) | 280 (32.2) | 0.606 |
| CTO (%)                      | 22 (2.5)   | 22 (2.5)   | 24 (2.8)   | 0.765 |
| Syntax score                 | 11.9 ± 8.4 | 11.9 ± 8.4 | 11.8 ± 8.3 | 0.716 |
| Length of stents             | 43.07 ± 28.16 | 43.07 ± 28.16 | 43.07 ± 28.16 | 0.856 |
| Diameter of stents           | 2.99 ± 0.66 | 3.01 ± 0.14 | 3.01 ± 1.24 | 0.302 |
| Number of stents             | 1.58 ± 0.93 | 1.60 ± 0.94 | 1.60 ± 0.94 | 0.717 |
| Use of GPs                   | 457 (15.1) | 457 (15.1) | 457 (15.1) | 0.888 |

PSM: propensity score matching; MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; SCAD: stable coronary artery disease; UA: unstable angina; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction; eGFR: estimated glomerular filtration rate; Hb: hemoglobin; LVEF: left ventricular ejection fraction; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor antagonist; CCB: calcium channel blocker; LM: left main; LAD: left anterior descending; LCX: left circumflex; RCA: right coronary artery; CTO: chronic total occlusion; GPIs: glycoprotein IIb/IIIa inhibitors. Data are presented as count (%) or mean ± standard deviation.
that in the UFH group. BARC 2, 3, and 5 bleeding was just numerically lower than bleeding rate in the bivalirudin group, the incidence of than those in the UFH group. Although there was a lower incidence of NACE. This finding was mainly ascribed to a significant reduction in bleeding and MACCE in the bivalirudin group. Regarding MACCE, patients in the bivalirudin group had a significantly lower mortality rate than those in the UFH group. Although there was a lower bleeding rate in the bivalirudin group, the incidence of BARC 2, 3, and 5 bleeding was just numerically lower than that in the UFH group.

The present study demonstrated that the benefit of MACCE in the bivalirudin group was mainly due to a significantly lower mortality at 30 days. In a post hoc analysis of HORIZONS-AMI, the rate of cardiac death was significantly lower in diabetic patients treated with bivalirudin than in those treated with UFH plus a GPI [18]. Similarly, in a pooled analysis of the REPLACE-2, ACUITY, and HORIZONS-AMI trials, bivalirudin was associated with reduced 1-year mortality in patients with DM [19]. Moreover, the most recently published randomized trial, the BRIGHT-4 study, found that bivalirudin with a prolonged infusion significantly reduced the 30-day mortality of patients with ST-segment elevation myocardial infarction undergoing PCI in comparison with heparin monotherapy [20]. The lower rate of death associated with bivalirudin use in patients with DM may have several explanations. First, diabetic patients with CAD tend to have fibrin-rich thrombi and platelet dysfunction [21]. Moreover, hyperglycaemia-induced upregulation of glycoproteins and increased expression of platelet activation markers boost the progression of atherosclerosis, leading to higher mortality and ischemic events in patients with DM than in those without DM [22, 23], which might also influence the pharmacodynamics of antiplatelet agents. Second, heparin can directly bind to the platelet glycoprotein IIb/IIIa receptor and increase platelet reactivity, thereby multiplying the risk of ischemic events in patients with DM; conversely, bivalirudin can not only inhibit circulating and clot-bound thrombin but also thrombin-induced platelet activation, with antiplatelet and anti-inflammatory effects similar to those of UFH plus a GPI [24, 25].

Regarding bleeding events, previous studies comparing bivalirudin with UFH in combination with a GPI in patients with DM have generated conflicting results [18, 26, 27]. The post hoc analysis of the ACUITY trial demonstrated a decrease in major bleeding with bivalirudin use in diabetic patients undergoing PCI [26, 28]; whereas, subgroup analyses from the HORIZONS-AMI and NAPLES studies showed no differences in major bleeding between bivalirudin and UFH [18, 27]. A meta-analysis found that the benefit of decreased major bleeding with bivalirudin was only seen when a GPI was mandated in the heparin group [29]. A recent randomized trial, VALIDATE-SWEDEHEART, which compared bivalirudin with heparin monotherapy in MI, also showed no significant difference with respect to major bleeding events [30]. In our study, bivalirudin monotherapy was associated with significantly lower bleeding than UFH monotherapy. With regard to BARC 2, 3, and 5 bleeding, although no difference was found between the two groups, just as in the above study, the rate of BARC 2, 3, and 5 bleeding in the UFH group was six times as high as that in the bivalirudin group. Moreover, for patients with chronic kidney disease, who are deemed as a special population with a high bleeding risk [31], our subgroup analysis showed that bivalirudin did not significantly increase the rate of bleeding. Given the 30-day mortality and bleeding benefits, the results of our study suggest that bivalirudin might be a better anticoagulant in patients with DM undergoing PCI than UFH.

### Table 2: 30-day clinical outcomes.

| Variable                  | Before PSM | After PSM |
|---------------------------|------------|-----------|
| NACE                      |            |           |
| Bivalirudin (n = 869)     | 26 (3.0)   | 26 (3.0)  |
| Heparin (n = 3021)        | 151 (5.0)  | 52 (6.0)  |
| P value                   | 0.012      | 0.003     |
| MACCE                     |            |           |
| Bivalirudin (n = 869)     | 15 (1.7)   | 15 (1.7)  |
| Heparin (n = 3021)        | 76 (2.5)   | 29 (3.3)  |
| P value                   | 0.175      | 0.033     |
| Death                     |            |           |
| Bivalirudin (n = 869)     | 5 (0.6)    | 5 (0.6)   |
| Heparin (n = 3021)        | 34 (1.1)   | 17 (2.0)  |
| P value                   | 0.151      | 0.010     |
| Nonfatal MI               |            |           |
| Bivalirudin (n = 869)     | 0          | 0         |
| Heparin (n = 3021)        | 1 (0)      | 1 (0)     |
| P value                   | 1.000      | 1.000     |
| Nonfatal stroke           |            |           |
| Bivalirudin (n = 869)     | 3 (0.3)    | 2 (0.3)   |
| Heparin (n = 3021)        | 4 (0.1)    | 2 (0.2)   |
| P value                   | 0.395      | 1.000     |
| uTLR                      |            |           |
| Bivalirudin (n = 869)     | 7 (0.8)    | 10 (1.2)  |
| Heparin (n = 3021)        | 38 (1.3)   | 4.655     |
| P value                   | 0.272      |           |

NACE: net adverse clinical event; MACCE: major adverse cardiovascular and cerebral event; MI: myocardial infarction; uTLR: urgent target lesion revascularization; BARC: bleeding academic research consortium. Data are presented as count (%).

### 4. Discussion

The main finding of this real-world observational study was that in patients with DM undergoing PCI, an antithrombotic regimen of bivalirudin monotherapy, compared with UFH monotherapy (without planned use of a GPI), was associated with a lower incidence of NACE. This finding was mainly ascribed to a significant reduction in bleeding and MACCE in the bivalirudin group. Regarding MACCE, patients in the bivalirudin group had a significantly lower mortality rate than those in the UFH group. Although there was a lower bleeding rate in the bivalirudin group, the incidence of BARC 2, 3, and 5 bleeding was just numerically lower than that in the UFH group.
Clinical trials evaluating the efficacy of bivalirudin in patients undergoing primary PCI obtained inconsistent results regarding ST at 30 days [6, 11, 30, 32]. In the HEAT-PPCI trial, the rate of 28-day ST in the bivalirudin group was significantly higher than that in the heparin group, while in the BRIGHT and VALIDATE-SWEDEHEART trials, there were no significant differences in the rate of 30-day ST between bivalirudin and heparin [11, 30, 32]. Bivalirudin in the HEAT-PPCI trial was used for a short duration, while in the present study, prolonged infusion of bivalirudin was given at the PCI dose during the PCI procedure and for at least 30 minutes after the procedure. Consistent with our study, all patients receiving bivalirudin in the BRIGHT trial and over 65% of patients receiving bivalirudin in the VALIDATE-SWEDEHEART trial received a prolonged infusion, and prolonged infusion appeared beneficial in terms of ST [30, 32]. A subgroup analysis of the MATRIX study also demonstrated that prolonged bivalirudin infusion at a full dose (1.75 mg/kg/h for ≤4 h) was associated with a significantly lower ST than no infusion, irrespective of the type of acute coronary syndrome (ACS) [33]. A meta-analysis including 13,505 patients from pivotal randomized trials demonstrated that bivalirudin with full dose post-PCI infusion is superior to heparin monotherapy in preventing early ST and major bleeding in patients who underwent primary PCI [34]. In terms of ST reported from our study, the rates of ST in both group were extremely low (0.2% in bivalirudin group and 0.1% in heparin group). Therefore, no significant
The difference in our study was found between bivalirudin and heparin due to the limited sample size, which led to a low event number of ST. Recently, the newest BRIGHT-4 study with a total sample size of more than 6000 patients with STEMI showed that bivalirudin with a prolonged infusion significantly decreased the rate of ST compared with heparin, indicating that bivalirudin has a substantial effect on preventing ST, to some extent, settled down this dispute [20].

Several limitations should be acknowledged in the present study. First, as an observational study, patients were not randomized according to antithrombotic strategy, and patients in the bivalirudin group were at higher risk of bleeding. Although PSM was performed, there may exist potential confounders between groups. Second, we only investigated 30-day clinical outcomes, and long-term follow-up will add further perspective. Third, patients who received heparin before the use of bivalirudin, a common phenomenon with potential benefits [30, 35, 36], were excluded per study protocol, which might limit the generalizability of our findings.

5. Conclusion

In this large, real-world cohort of patients with DM undergoing PCI, bivalirudin, compared with UFH monotherapy, was significantly associated with a reduction in 30-day NACE and MACCE, mainly driven by the significantly lower incidences of bleeding and mortality.
Data Availability

The data in this study is available with reasonable requests by contacting the corresponding authors.

Additional Points

Key Summary Points. Why carry out a study? Previous trials mostly compared bivalirudin with UFH plus GPI, while concomitant use of GPI is considered only for bail-out in current guidelines according to risk of bleeding. Currently, evidences comparing bivalirudin with UFH monotherapy are limited, especially among diabetic patients undergoing PCI. What was learned from the study? This large-sample, observational study found that in diabetic patients undergoing PCI, bivalirudin was significantly associated with a significantly lower risk of 30-day NACE, driven by a lower bleeding and MACCE, and a significantly lower mortality, compared with heparin monotherapy. What were the study conclusions? In addition to improving our understanding of the precise effects of bivalirudin and heparin in contemporary clinical practice, these findings emphasize the benefit of bivalirudin versus heparin monotherapy in reducing 30-day mortality in diabetic patients.

Ethical Approval

This retrospective study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of General Hospital of Northern Theater Command, and an exemption for informed consent was approved simultaneously.

Consent

An exemption for informed consent was approved by the Ethics Committee of General Hospital of Northern Theater Command.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Jing Li and Yi Li were mainly in charge of conducting this observational study. Sanbao Chen and Sicong Ma were in charge of manuscript writing. Mingque Yang and Zizhao Qi contributed to recruiting subjects during the whole period of study. Kun Na and Miaohan Qiu were in charge of statistical analysis. The corresponding author, Yaling Han, contributed to the leadership of the whole study conduct and acted as the key role of designing, initiating, and conducting this study. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgments

The authors acknowledge all contributors from the General Hospital of Northern Theater Command to this study. This study was supported by the National Key Research and Development Project in China (ID: 2021YFC2501602) and the Liaoning S&T Project in Liaoning Province, China (ID: 2020020292-JH1/103-03).

Supplementary Materials

Table S1 was shown in the supplemental materials. (Supplementary Materials)

References

[1] M. Roffi and E. J. Topol, “Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes,” European heart journal, vol. 25, no. 3, pp. 190–198, 2004.
[2] L. C. Godoy, V. Rao, and M. E. Farkouh, “Coronary revascularization of patients with diabetes mellitus in the setting of acute coronary syndromes,” Circulation, vol. 140, no. 15, pp. 1233–1235, 2019.
[3] R. Mehran, S. Pocock, E. Nikolsky et al., “Impact of bleeding on mortality after percutaneous coronary intervention: results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUTY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials,” JACC Cardiovascular interventions, vol. 4, no. 6, pp. 654–664, 2011.
[4] S. James, D. J. Angiolillo, J. H. Cornel et al., “Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATElet inhibition and patient outcomes (PLATO) trial,” European Heart Journal, vol. 31, no. 24, pp. 3006–3016, 2010.
[5] G. Gargiulo, S. Windecker, B. R. da Costa et al., “Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials,” BMJ, vol. 355, article i5483, 2016.
[6] G. W. Stone, B. Witzbenbichler, G. Guagliumi et al., “Bivalirudin during primary PCI in acute myocardial infarction,” The New England Journal of Medicine, vol. 358, no. 21, pp. 2218–2230, 2008.
[7] G. W. Stone, B. T. McLaurin, D. A. Cox et al., “Bivalirudin for patients with acute coronary syndromes,” The New England journal of medicine, vol. 355, no. 21, pp. 2203–2216, 2006.
[8] P. G. Steg, A. van’t Hof, C. W. Hamm et al., “Bivalirudin started during emergency transport for primary PCI,” The New England journal of Medicine, vol. 369, no. 23, pp. 2207–2217, 2013.
[9] M. Valgimigli, E. Frigoli, S. Leonardi et al., “Bivalirudin or unfractionated heparin in acute coronary syndromes,” The New England journal of medicine, vol. 373, no. 11, pp. 997–1009, 2015.
[10] M. A. Cavender and M. S. Sabatine, "Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials," The Lancet, vol. 384, no. 9943, pp. 599–606, 2014.

[11] A. Shahzad, I. Kemp, C. Mars et al., "Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial," The Lancet, vol. 384, no. 9957, pp. 1849–1858, 2014.

[12] G. W. Stone, R. Mehran, P. Goldstein et al., "Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials," Journal of the American College of Cardiology, vol. 65, no. 1, pp. 27–38, 2015.

[13] J. P. Collet, H. Thiele, E. Barbato et al., "2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation," European Heart Journal, vol. 42, no. 14, pp. 1289–1367, 2021.

[14] F. J. Neumann, M. Sousa-Uva, A. Ahlsson et al., "2018 ESC/EACTS Guidelines on myocardial revascularization," European heart journal, vol. 40, no. 2, pp. 87–165, 2019.

[15] K. Thygesen, J. S. Alpert, A. S. Jaffe et al., "Fourth universal definition of myocardial infarction (2018)," Journal of the American College of Cardiology, vol. 72, no. 18, pp. 2231–2264, 2018.

[16] R. Mehran, S. V. Rao, D. L. Bhatt et al., "Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium," Circulation, vol. 123, no. 23, pp. 2736–2747, 2011.

[17] D. E. Cutlip, S. Windecker, R. Mehran et al., "Clinical end points in coronary stent trials," Circulation, vol. 115, no. 17, pp. 2344–2351, 2007.

[18] B. Witzenbichler, R. Mehran, G. Guagliumi et al., "Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization-iZatiON and stents in acute myocardial infarction) trial," JACC Cardiovascular interventions, vol. 4, no. 7, pp. 760–768, 2011.

[19] G. Giustino, R. Mehran, S. Bansilal et al., "Safety and efficacy of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention: from the REPLACE-2, ACUTY and HORIZONS-AMI trials," The American Journal of Cardiology, vol. 118, no. 1, pp. 6–16, 2016.

[20] Y. Li, Z. Liang, L. Qin et al., "Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial," The Lancet, 2022.

[21] G. N. Viswanathan, S. M. Marshall, K. Balasubramaniam, J. J. Badimon, and A. G. Zaman, "Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome," Thrombosis research, vol. 133, no. 5, pp. 880–885, 2014.

[22] Authors/Task Force, L. Rydén, P. J. Grant et al., "ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD," European heart journal, vol. 34, no. 39, pp. 3035–3087, 2013.

[23] A. Rawshani, A. Rawshani, S. Franzén et al., "Mortality and cardiovascular disease in type 1 and type 2 diabetes," The New England journal of medicine, vol. 376, no. 15, pp. 1407–1418, 2017.

[24] E. I. Lev, R. Patel, A. Karim, A. Kleiman, J. Badimon, and N. Kleiman, "Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study," Thrombosis and haemostasis, vol. 95, no. 3, pp. 441–446, 2006.

[25] F. K. Keating, H. L. Dauerman, D. A. Whitaker, B. E. Sobel, and D. J. Schneider, "The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention," Coronary artery disease, vol. 16, no. 6, pp. 401–405, 2005.

[26] F. Feit, S. V. Manoukian, R. Ebrahimie et al., "Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (acute catheterization and urgent intervention triage strategy) trial," Journal of the American College of Cardiology, vol. 51, no. 17, pp. 1645–1652, 2008.

[27] D. Tavano, G. Visconti, D. D’Andrea et al., "Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention," The American Journal of Cardiology, vol. 104, no. 9, pp. 1222–1228, 2009.

[28] G. W. Stone, M. Bertrand, A. Colombo et al., "Acute catheterization and urgent intervention triage strategy (ACUTY) trial: study design and rationale," American Heart Journal, vol. 148, no. 5, pp. 764–775, 2004.

[29] R. Nairoor, P. Sardar, H. Amin, S. Chatterjee, T. Helmy, and S. S. Naidu, "Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with aspirin and clopidogrel in patients with diabetes mellitus undergoing elective percutaneous coronary intervention: a meta-analysis of randomized trials," Catheterization and cardiovascular interventions: official journal of the Society for Cardiovascular Angiography & Interventions, vol. 86, no. 3, pp. 364–375, 2015.

[30] D. Erlinge, E. Omerovic, O. Fröbert et al., "Bivalirudin versus heparin monotherapy in myocardial infarction," The New England Journal of Medicine, vol. 377, no. 12, pp. 1132–1142, 2017.

[31] O. De Filippo, F. D’Ascenzo, S. Raposeiras-Roubin et al., "P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects," European Heart Journal-Cardiovascular Pharmacotherapy, vol. 6, no. 1, pp. 31–42, 2020.

[32] Y. Han, J. Guo, Y. Zheng et al., "Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction," Journal of the American Medical Association, vol. 313, no. 13, pp. 1336–1346, 2015.

[33] G. Gargiulo, G. Carella, E. Frigoli et al., "Post-procedural bivalirudin infusion at full or low regimen in patients with acute coronary syndrome," Journal of the American College of Cardiology, vol. 73, no. 7, pp. 758–774, 2019.

[34] R. Shah, S. B. Latham, J. M. Porta, L. V. Matin, and S. V. Rao, "Bivalirudin with a post-procedure infusion versus heparin monotherapy for the prevention of stent thrombosis," Catheterization and Cardiovascular Interventions, vol. 94, no. 2, pp. 210–215, 2019.
[35] G. D. Dangas, A. Caixeta, R. Mehran et al., "Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction," *Circulation*, vol. 123, no. 16, pp. 1745–1756, 2011.

[36] R. Shah, I. S. Jovin, A. Chaudhry et al., "Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention," *Catheterization and Cardiovascular Interventions*, vol. 93, no. 2, pp. 241–247, 2019.